LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 61

Search options

  1. Article ; Online: Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.

    Taquet, Maxime / Skorniewska, Zuzanna / Zetterberg, Henrik / Geddes, John R / Mummery, Catherine J / Chalmers, James D / Ho, Ling-Pei / Horsley, Alex / Marks, Michael / Poinasamy, Krisnah / Raman, Betty / Leavy, Olivia C / Richardson, Matthew / Elneima, Omer / McAuley, Hamish J C / Shikotra, Aarti / Singapuri, Amisha / Sereno, Marco / Saunders, Ruth M /
    Harris, Victoria Claire / Houchen-Wolloff, Linzy / Mansoori, Parisa / Greening, Neil J / Harrison, Ewen M / Docherty, Annemarie B / Lone, Nazir I / Quint, Jennifer / Greenhalf, William / Wain, Louise V / Brightling, Christopher E / Evans, Rachael E / Harrison, Paul J / Koychev, Ivan

    Brain communications

    2023  Volume 6, Issue 1, Page(s) fcad357

    Abstract: A proportion of patients infected with severe acute respiratory syndrome coronavirus 2 experience a range of neuropsychiatric symptoms months after infection, including cognitive deficits, depression and anxiety. The mechanisms underpinning such symptoms ...

    Abstract A proportion of patients infected with severe acute respiratory syndrome coronavirus 2 experience a range of neuropsychiatric symptoms months after infection, including cognitive deficits, depression and anxiety. The mechanisms underpinning such symptoms remain elusive. Recent research has demonstrated that nervous system injury can occur during COVID-19. Whether ongoing neural injury in the months after COVID-19 accounts for the ongoing or emergent neuropsychiatric symptoms is unclear. Within a large prospective cohort study of adult survivors who were hospitalized for severe acute respiratory syndrome coronavirus 2 infection, we analysed plasma markers of nervous system injury and astrocytic activation, measured 6 months post-infection: neurofilament light, glial fibrillary acidic protein and total tau protein. We assessed whether these markers were associated with the severity of the acute COVID-19 illness and with post-acute neuropsychiatric symptoms (as measured by the Patient Health Questionnaire for depression, the General Anxiety Disorder assessment for anxiety, the Montreal Cognitive Assessment for objective cognitive deficit and the cognitive items of the Patient Symptom Questionnaire for subjective cognitive deficit) at 6 months and 1 year post-hospital discharge from COVID-19. No robust associations were found between markers of nervous system injury and severity of acute COVID-19 (except for an association of small effect size between duration of admission and neurofilament light) nor with post-acute neuropsychiatric symptoms. These results suggest that ongoing neuropsychiatric symptoms are not due to ongoing neural injury.
    Language English
    Publishing date 2023-12-27
    Publishing country England
    Document type Journal Article
    ISSN 2632-1297
    ISSN (online) 2632-1297
    DOI 10.1093/braincomms/fcad357
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Ciliopathy patient variants reveal organelle-specific functions for TUBB4B in axonemal microtubules.

    Dodd, Daniel O / Mechaussier, Sabrina / Yeyati, Patricia L / McPhie, Fraser / Anderson, Jacob R / Khoo, Chen Jing / Shoemark, Amelia / Gupta, Deepesh K / Attard, Thomas / Zariwala, Maimoona A / Legendre, Marie / Bracht, Diana / Wallmeier, Julia / Gui, Miao / Fassad, Mahmoud R / Parry, David A / Tennant, Peter A / Meynert, Alison / Wheway, Gabrielle /
    Fares-Taie, Lucas / Black, Holly A / Mitri-Frangieh, Rana / Faucon, Catherine / Kaplan, Josseline / Patel, Mitali / McKie, Lisa / Megaw, Roly / Gatsogiannis, Christos / Mohamed, Mai A / Aitken, Stuart / Gautier, Philippe / Reinholt, Finn R / Hirst, Robert A / O'Callaghan, Chris / Heimdal, Ketil / Bottier, Mathieu / Escudier, Estelle / Crowley, Suzanne / Descartes, Maria / Jabs, Ethylin W / Kenia, Priti / Amiel, Jeanne / Bacci, Giacomo Maria / Calogero, Claudia / Palazzo, Viviana / Tiberi, Lucia / Blümlein, Ulrike / Rogers, Andrew / Wambach, Jennifer A / Wegner, Daniel J / Fulton, Anne B / Kenna, Margaret / Rosenfeld, Margaret / Holm, Ingrid A / Quigley, Alan / Hall, Emma A / Murphy, Laura C / Cassidy, Diane M / von Kriegsheim, Alex / Papon, Jean-François / Pasquier, Laurent / Murris, Marlène S / Chalmers, James D / Hogg, Claire / Macleod, Kenneth A / Urquhart, Don S / Unger, Stefan / Aitman, Timothy J / Amselem, Serge / Leigh, Margaret W / Knowles, Michael R / Omran, Heymut / Mitchison, Hannah M / Brown, Alan / Marsh, Joseph A / Welburn, Julie P I / Ti, Shih-Chieh / Horani, Amjad / Rozet, Jean-Michel / Perrault, Isabelle / Mill, Pleasantine

    Science (New York, N.Y.)

    2024  Volume 384, Issue 6694, Page(s) eadf5489

    Abstract: Tubulin, one of the most abundant cytoskeletal building blocks, has numerous isotypes in metazoans encoded by different conserved genes. Whether these distinct isotypes form cell type- and context-specific microtubule structures is poorly understood. ... ...

    Abstract Tubulin, one of the most abundant cytoskeletal building blocks, has numerous isotypes in metazoans encoded by different conserved genes. Whether these distinct isotypes form cell type- and context-specific microtubule structures is poorly understood. Based on a cohort of 12 patients with primary ciliary dyskinesia as well as mouse mutants, we identified and characterized variants in the
    MeSH term(s) Tubulin/genetics ; Tubulin/metabolism ; Humans ; Animals ; Microtubules/metabolism ; Mice ; Cilia/metabolism ; Axoneme/metabolism ; Centrioles/metabolism ; Ciliopathies/genetics ; Ciliopathies/metabolism ; Ciliary Motility Disorders/genetics ; Ciliary Motility Disorders/metabolism ; Protein Isoforms/genetics ; Protein Isoforms/metabolism ; Mutation
    Chemical Substances Tubulin ; Protein Isoforms
    Language English
    Publishing date 2024-04-26
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 128410-1
    ISSN 1095-9203 ; 0036-8075
    ISSN (online) 1095-9203
    ISSN 0036-8075
    DOI 10.1126/science.adf5489
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey.

    van Ingen, Jakko / Aliberti, Stefano / Andrejak, Claire / Chalmers, James D / Codecasa, Luigi R / Daley, Charles L / Hasegawa, Naoki / Griffith, David E / Hoefsloot, Wouter / Huitt, Gwen / Jarand, Julie / Jhun, Byung Woo / Loebinger, Michael R / Marras, Theodore K / Morimoto, Kozo / Polverino, Eva / Ringshausen, Felix C / Santin, Miguel / Thomson, Rachel /
    Wagner, Dirk / Wallace, Richard J / Winthrop, Kevin L / Yim, Jae-Joon

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Volume 73, Issue 1, Page(s) e256–e259

    Abstract: Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ... ...

    Abstract Adverse events are frequent in nontuberculous mycobacteria pulmonary disease treatment, but evidence to support their management is scarce. An expert panel survey on management of adverse events shows consistent opinions on management of hepatoxicity, ocular toxicity, ototoxicity, tinnitus, and gastrointestinal upset. These opinions can provide assistance in individual patient management decisions.
    MeSH term(s) Drug-Related Side Effects and Adverse Reactions ; Humans ; Lung Diseases/chemically induced ; Mycobacterium Infections, Nontuberculous ; Mycobacterium avium Complex ; Mycobacterium avium-intracellulare Infection/drug therapy ; Nontuberculous Mycobacteria
    Language English
    Publishing date 2020-09-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa1361
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Correction: The effect of COVID rehabilitation for ongoing symptoms Post HOSPitalisation with COVID-19 (PHOSP-R): protocol for a randomised parallel group controlled trial on behalf of the PHOSP consortium.

    Daynes, Enya / Baldwin, Molly / Greening, Neil J / Yates, Thomas / Bishop, Nicolette C / Mills, George / Roberts, Matthew / Hamrouni, Malik / Plekhanova, Tatiana / Vogiatzis, Ioannis / Echevarria, Carlos / Nathu, Rashmita / McAuley, Hamish J C / Latimer, Lorna / Glennie, Jennifer / Chambers, Francesca / Penfold, Ruth / Hume, Emily / Megaritis, Dimitrios /
    Alexiou, Charikleia / Potthof, Sebastian / Hogg, Mitchell James / Haighton, Catherine / Nichol, Bethany / Leavy, Olivia C / Richardson, Matthew / Elneima, Omer / Singapuri, Amisha / Sereno, Marco / Saunders, Ruth M / Harris, Victoria C / Nolan, Claire M / Bolton, Charlotte / Houchen-Wolloff, Linzy / Harrison, Ewen M / Lone, Nazir / Quint, Jennifer / Chalmers, James D / Ho, Ling-Pei / Horsley, Alex / Marks, Michael / Poinasamy, Krisnah / Ramen, Betty / Wain, Louise V / Brightling, Christopher / Man, William D-C / Evans, Rachael / Singh, Sally J

    Trials

    2023  Volume 24, Issue 1, Page(s) 98

    Language English
    Publishing date 2023-02-07
    Publishing country England
    Document type Published Erratum
    ZDB-ID 2040523-6
    ISSN 1745-6215 ; 1468-6694 ; 1745-6215
    ISSN (online) 1745-6215
    ISSN 1468-6694 ; 1745-6215
    DOI 10.1186/s13063-023-07132-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The effect of COVID rehabilitation for ongoing symptoms Post HOSPitalisation with COVID-19 (PHOSP-R): protocol for a randomised parallel group controlled trial on behalf of the PHOSP consortium.

    Daynes, Enya / Baldwin, Molly / Greening, Neil J / Yates, Thomas / Bishop, Nicolette C / Mills, George / Roberts, Matthew / Hamrouni, Malik / Plekhanova, Tatiana / Vogiatzis, Ioannis / Echevarria, Carlos / Nathu, Rashmita / McAuley, Hamish J C / Latimer, Lorna / Glennie, Jennifer / Chambers, Francesca / Penfold, Ruth / Hume, Emily / Megaritis, Dimitrios /
    Alexiou, Charikleia / Potthoff, Sebastian / Hogg, Mitchell James / Haighton, Catherine / Nichol, Bethany / Leavy, Olivia C / Richardson, Matthew / Elneima, Omer / Singapuri, Amisha / Sereno, Marco / Saunders, Ruth M / Harris, Victoria C / Nolan, Claire M / Bolton, Charlotte / Houchen-Wolloff, Linzy / Harrison, Ewen M / Lone, Nazir / Quint, Jennifer / Chalmers, James D / Ho, Ling-Pei / Horsley, Alex / Marks, Michael / Poinasamy, Krisnah / Ramen, Betty / Wain, Louise V / Brightling, Christopher / Man, William D-C / Evans, Rachael / Singh, Sally J

    Trials

    2023  Volume 24, Issue 1, Page(s) 61

    Abstract: Introduction: Many adults hospitalised with COVID-19 have persistent symptoms such as fatigue, breathlessness and brain fog that limit day-to-day activities. These symptoms can last over 2 years. Whilst there is limited controlled studies on ... ...

    Abstract Introduction: Many adults hospitalised with COVID-19 have persistent symptoms such as fatigue, breathlessness and brain fog that limit day-to-day activities. These symptoms can last over 2 years. Whilst there is limited controlled studies on interventions that can support those with ongoing symptoms, there has been some promise in rehabilitation interventions in improving function and symptoms either using face-to-face or digital methods, but evidence remains limited and these studies often lack a control group.
    Methods and analysis: This is a nested single-blind, parallel group, randomised control trial with embedded qualitative evaluation comparing rehabilitation (face-to-face or digital) to usual care and conducted within the PHOSP-COVID study. The aim of this study is to determine the effectiveness of rehabilitation interventions on exercise capacity, quality of life and symptoms such as breathlessness and fatigue. The primary outcome is the Incremental Shuttle Walking Test following the eight week intervention phase. Secondary outcomes include measures of function, strength and subjective assessment of symptoms. Blood inflammatory markers and muscle biopsies are an exploratory outcome. The interventions last eight weeks and combine symptom-titrated exercise therapy, symptom management and education delivered either in a face-to-face setting or through a digital platform ( www.yourcovidrecovery.nhs.uk ). The proposed sample size is 159 participants, and data will be intention-to-treat analyses comparing rehabilitation (face-to-face or digital) to usual care.
    Ethics and dissemination: Ethical approval was gained as part of the PHOSP-COVID study by Yorkshire and the Humber Leeds West Research NHS Ethics Committee, and the study was prospectively registered on the ISRCTN trial registry (ISRCTN13293865). Results will be disseminated to stakeholders, including patients and members of the public, and published in appropriate journals. Strengths and limitations of this study • This protocol utilises two interventions to support those with ongoing symptoms of COVID-19 • This is a two-centre parallel-group randomised controlled trial • The protocol has been supported by patient and public involvement groups who identified treatments of symptoms and activity limitation as a top priority.
    MeSH term(s) Adult ; Humans ; COVID-19 ; Quality of Life ; Single-Blind Method ; Dyspnea ; Fatigue/diagnosis ; Fatigue/etiology ; Randomized Controlled Trials as Topic
    Language English
    Publishing date 2023-01-26
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2040523-6
    ISSN 1745-6215 ; 1468-6694 ; 1745-6215
    ISSN (online) 1745-6215
    ISSN 1468-6694 ; 1745-6215
    DOI 10.1186/s13063-023-07093-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Joint patient and clinician priority setting to identify 10 key research questions regarding the long-term sequelae of COVID-19.

    Houchen-Wolloff, Linzy / Poinasamy, Krisnah / Holmes, Kate / Tarpey, Maryrose / Hastie, Claire / Raihani, Kelly / Rogers, Natalie / Smith, Nikki / Adams, Dawn / Burgess, Paul / Clark, Jean / Cranage, Clare / Desai, Mahadev / Geary, Nicola / Gill, Rhyan / Mangwani, Jitendra / Staunton, Lily / Berry, Colin / Bolton, Charlotte E /
    Chalder, Trudie / Chalmers, James / De Soyza, Anthony / Elneima, Omer / Geddes, John / Heller, Simon / Ho, Ling-Pei / Jacob, Joseph / McAuley, Hamish / Parmar, Aarti / Quint, Jennifer K / Raman, Betty / Rowland, Matthew / Singapuri, Amisha / Singh, Sally J / Thomas, David / Toshner, Mark R / Wain, Louise V / Horsley, Alex Robert / Marks, Michael / Brightling, Christopher E / Evans, Rachael A

    Thorax

    2022  Volume 77, Issue 7, Page(s) 717–720

    Abstract: Given the large numbers of people infected and high rates of ongoing morbidity, research is clearly required to address the needs of adult survivors of COVID-19 living with ongoing symptoms (long COVID). To help direct resource and research efforts, we ... ...

    Abstract Given the large numbers of people infected and high rates of ongoing morbidity, research is clearly required to address the needs of adult survivors of COVID-19 living with ongoing symptoms (long COVID). To help direct resource and research efforts, we completed a research prioritisation process incorporating views from adults with ongoing symptoms of COVID-19, carers, clinicians and clinical researchers. The final top 10 research questions were agreed at an independently mediated workshop and included: identifying underlying mechanisms of long COVID, establishing diagnostic tools, understanding trajectory of recovery and evaluating the role of interventions both during the acute and persistent phases of the illness.
    MeSH term(s) Adult ; COVID-19/complications ; Caregivers ; Disease Progression ; Health Priorities ; Humans ; Research Personnel ; Post-Acute COVID-19 Syndrome
    Language English
    Publishing date 2022-03-30
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 204353-1
    ISSN 1468-3296 ; 0040-6376
    ISSN (online) 1468-3296
    ISSN 0040-6376
    DOI 10.1136/thoraxjnl-2021-218582
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Therapeutic Inertia With Initial Low-Dose Quadruple Combination Therapy for Hypertension: Results From the QUARTET Trial.

    Wang, Nelson / Von Huben, Amy / Marschner, Simone / Nelson, Mark R / Nolde, Janis M / Schlaich, Markus P / Figtree, Gemma / Hillis, Graham S / Usherwood, Tim / Reid, Christopher M / Chalmers, John / Jansen, Shirley / Atkins, Emily R / Billot, Laurent / Chow, Clara / Rodgers, Anthony

    Hypertension (Dallas, Tex. : 1979)

    2024  Volume 81, Issue 5, Page(s) 1087–1094

    Abstract: Background: Low-dose combinations are a promising intervention for improving blood pressure (BP) control but their effects on therapeutic inertia are uncertain.: Methods: Analysis of 591 patients randomized to an ultra-low-dose quadruple pill or ... ...

    Abstract Background: Low-dose combinations are a promising intervention for improving blood pressure (BP) control but their effects on therapeutic inertia are uncertain.
    Methods: Analysis of 591 patients randomized to an ultra-low-dose quadruple pill or initial monotherapy. The episode of therapeutic inertia was defined as a patient visit with a BP of >140/90 mm Hg without intensification of antihypertensive treatment. We compared the frequency of therapeutic inertia episodes between Quadpill and initial monotherapy as a proportion of the total population (intention-to-treat analysis with the denominator being all participants randomized) and as a proportion of people with uncontrolled BP (with the denominator being participants with uncontrolled BP).
    Results: Therapeutic inertia occurred in fewer participants randomized to Quadpill compared with monotherapy. For example, among the 390 participants with a 6-month follow-up, therapeutic inertia according to unattended BP was 21/192 (11%) versus 45/192 (23%),
    Conclusions: Among all treated individuals, low-dose Quadpill reduced the number of therapeutic inertia episodes compared with initial monotherapy. After the first follow-up visit, most high BP values did not lead to treatment intensification in both groups. Education is needed about the importance of treatment intensification despite a significant improvement in BP or BP being close to target.
    Registration: URL: https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12616001144404; Unique identifier: ACTRN12616001144404.
    MeSH term(s) Humans ; Hypertension ; Antihypertensive Agents/therapeutic use ; Blood Pressure ; Combined Modality Therapy ; Medication Adherence
    Chemical Substances Antihypertensive Agents
    Language English
    Publishing date 2024-03-13
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 423736-5
    ISSN 1524-4563 ; 0194-911X ; 0362-4323
    ISSN (online) 1524-4563
    ISSN 0194-911X ; 0362-4323
    DOI 10.1161/HYPERTENSIONAHA.123.22284
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.

    Shoemark, Amelia / Griffin, Helen / Wheway, Gabrielle / Hogg, Claire / Lucas, Jane S / Camps, Carme / Taylor, Jenny / Carroll, Mary / Loebinger, Michael R / Chalmers, James D / Morris-Rosendahl, Deborah / Mitchison, Hannah M / De Soyza, Anthony / Brown, D / Ambrose, J C / Arumugam, P / Bevers, R / Bleda, M / Boardman-Pretty, F /
    Boustred, C R / Brittain, H / Caulfield, M J / Chan, G C / Fowler, T / Giess, A / Hamblin, A / Henderson, S / Hubbard, T J P / Jackson, R / Jones, L J / Kasperaviciute, D / Kayikci, M / Kousathanas, A / Lahnstein, L / Leigh, S E A / Leong, I U S / Lopez, F J / Maleady-Crowe, F / McEntagart, M / Minneci, F / Moutsianas, L / Mueller, M / Murugaesu, N / Need, A C / O'Donovan, P / Odhams, C A / Patch, C / Perez-Gil, D / Pereira, M B / Pullinger, J / Rahim, T / Rendon, A / Rogers, T / Savage, K / Sawant, K / Scott, R H / Siddiq, A / Sieghart, A / Smith, S C / Sosinsky, A / Stuckey, A / Tanguy, M / Taylor Tavares, A L / Thomas, E R A / Thompson, S R / Tucci, A / Welland, M J / Williams, E / Witkowska, K / Wood, S M

    The European respiratory journal

    2022  Volume 60, Issue 5

    Abstract: Background: Bronchiectasis can result from infectious, genetic, immunological and allergic causes. 60-80% of cases are idiopathic, but a well-recognised genetic cause is the motile ciliopathy, primary ciliary dyskinesia (PCD). Diagnosis of PCD has ... ...

    Abstract Background: Bronchiectasis can result from infectious, genetic, immunological and allergic causes. 60-80% of cases are idiopathic, but a well-recognised genetic cause is the motile ciliopathy, primary ciliary dyskinesia (PCD). Diagnosis of PCD has management implications including addressing comorbidities, implementing genetic and fertility counselling and future access to PCD-specific treatments. Diagnostic testing can be complex; however, PCD genetic testing is moving rapidly from research into clinical diagnostics and would confirm the cause of bronchiectasis.
    Methods: This observational study used genetic data from severe bronchiectasis patients recruited to the UK 100,000 Genomes Project and patients referred for gene panel testing within a tertiary respiratory hospital. Patients referred for genetic testing due to clinical suspicion of PCD were excluded from both analyses. Data were accessed from the British Thoracic Society audit, to investigate whether motile ciliopathies are underdiagnosed in people with bronchiectasis in the UK.
    Results: Pathogenic or likely pathogenic variants were identified in motile ciliopathy genes in 17 (12%) out of 142 individuals by whole-genome sequencing. Similarly, in a single centre with access to pathological diagnostic facilities, 5-10% of patients received a PCD diagnosis by gene panel, often linked to normal/inconclusive nasal nitric oxide and cilia functional test results. In 4898 audited patients with bronchiectasis, <2% were tested for PCD and <1% received genetic testing.
    Conclusions: PCD is underdiagnosed as a cause of bronchiectasis. Increased uptake of genetic testing may help to identify bronchiectasis due to motile ciliopathies and ensure appropriate management.
    MeSH term(s) Humans ; Mutation ; Bronchiectasis/diagnosis ; Bronchiectasis/genetics ; Cilia ; Ciliary Motility Disorders/diagnosis ; Ciliary Motility Disorders/genetics ; Ciliopathies/complications ; Kartagener Syndrome/diagnosis ; Kartagener Syndrome/genetics
    Language English
    Publishing date 2022-11-17
    Publishing country England
    Document type Observational Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639359-7
    ISSN 1399-3003 ; 0903-1936
    ISSN (online) 1399-3003
    ISSN 0903-1936
    DOI 10.1183/13993003.00176-2022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Evaluation of the Panbio™ COVID-19 IgG rapid test device performance.

    Moy, James N / Amin, Ariff Mohammed / Chalmers-Watson, Claire / Chowdhury, Rezwona / Forssten, Camilla / Fu, Jun / Ghosh, Sarit / Harris, Jeffrey D / Kordowich, Simon / Li, Yin / Lin, Wenchi / Mackay-Thomas, Stuart / Mickiewicz, Marc / Patel, Nikesh / Resino, Salvador / Sevenoaks, Tamsin / Tugetman, Michael A / Valencia, Jorge / Vijesurier, Roy /
    White, Nikki / Woods, Christopher W / Kennedy, Patrick T / Ryan, Pablo

    Heliyon

    2023  Volume 9, Issue 12, Page(s) e22612

    Abstract: Background: The Panbio™ COVID-19 IgG Rapid Test Device ("Panbio™") detects IgG antibodies against the SARS-CoV-2 spike protein from viral infection or vaccination.: Objectives: To determine the diagnostic sensitivity and specificity of the Panbio™ ... ...

    Abstract Background: The Panbio™ COVID-19 IgG Rapid Test Device ("Panbio™") detects IgG antibodies against the SARS-CoV-2 spike protein from viral infection or vaccination.
    Objectives: To determine the diagnostic sensitivity and specificity of the Panbio™ professional use test, using fingerstick whole blood and venous plasma.
    Study design: Fingerstick whole blood and venous plasma from each participant were tested with Panbio™ and compared against the SARS-CoV-2 IgG II assay on the Abbott Architect™ platform (Europe) or the equivalent AdviseDx SARS-CoV-2 IgG II Abbott Alinity i™ platform (US). 447 evaluable participants were enrolled across 6 US and 9 European clinical centers.
    Results: For unvaccinated participants with PCR-confirmed infection ≥21 days post-symptom onset, the Panbio™ sensitivity with fingerstick whole blood was 92.6 % (95 % CI: 85.9, 96.7), and the specificity was 97.0 % (95 % CI: 93.1, 99.0). For venous plasma, the sensitivity was 90.0 % (95 % CI: 79.5, 96.2) for participants with PCR-confirmed infection and symptom onset 22-180 days ago; the specificity was 96.3 % (92.2, 98.6). For vaccinated participants, the sensitivity was 98.4 % (95 % CI: 91.2, 100.0) for fingerstick whole blood and 96.7 % (95 % CI: 88.7, 99.6) for venous plasma.
    Conclusion: The Panbio™ test had high sensitivity and specificity for detecting IgG against the SARS-CoV-2 spike protein.
    Language English
    Publishing date 2023-11-22
    Publishing country England
    Document type Journal Article
    ZDB-ID 2835763-2
    ISSN 2405-8440
    ISSN 2405-8440
    DOI 10.1016/j.heliyon.2023.e22612
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Ambulatory blood pressure after 12 weeks of quadruple combination of quarter doses of blood pressure medication vs. standard medication.

    Nolde, Janis M / Atkins, Emily / Marschner, Simone / Hillis, Graham S / Chalmers, John / Billiot, Laurent / Nelson, Mark R / Reid, Christopher M / Hay, Peter / Burke, Michael / Jansen, Shirley / Usherwood, Tim / Rodgers, Anthony / Chow, Clara K / Schlaich, Markus P

    Journal of hypertension

    2024  Volume 42, Issue 6, Page(s) 1009–1018

    Abstract: Background: A combination of four ultra-low-dose blood pressure (BP) medications lowered office BP more effectively than initial monotherapy in the QUARTET trial. The effects on average ambulatory BP changes at 12 weeks have not yet been reported in ... ...

    Abstract Background: A combination of four ultra-low-dose blood pressure (BP) medications lowered office BP more effectively than initial monotherapy in the QUARTET trial. The effects on average ambulatory BP changes at 12 weeks have not yet been reported in detail.
    Methods: Adults with hypertension who were untreated or on monotherapy were eligible for participation. Overall, 591 participants were randomized to either the quadpill (irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg) or monotherapy control (irbesartan 150 mg). The difference in 24-h, daytime, and night-time systolic and diastolic ambulatory BP at 12 weeks along further metrics were predefined secondary outcomes.
    Results: Of 576 participants, 289 were randomized to the quadpill group and 287 to the monotherapy group. At 12 weeks, mean 24-h ambulatory SBP and DBP were 7.7 [95% confidence interval (95% CI) 9.6-5.8] and 5.3 (95% CI: 6.5-4.1) mmHg lower in the quadpill vs. monotherapy group ( P  < 0.001 for both). Similar reductions in the quadpill group were observed for daytime (8.1/5.7 mmHg lower) and night-time (6.3/4.0 mmHg lower) BP at 12 weeks (all P  < 0.001) compared to monotherapy. The rate of BP control (24-h average BP < 130/80 mmHg) at 12 weeks was higher in the quadpill group (77 vs. 50%; P  < 0.001). The reduction in BP load was also more pronounced with the quadpill.
    Conclusion: A quadruple quarter-dose combination compared with monotherapy resulted in greater ambulatory BP lowering across the entire 24-h period with higher ambulatory BP control rates and reduced BP variability at 12 weeks. These findings further substantiate the efficacy of an ultra-low-dose quadpill-based BP lowering strategy.
    MeSH term(s) Humans ; Antihypertensive Agents/administration & dosage ; Antihypertensive Agents/therapeutic use ; Blood Pressure Monitoring, Ambulatory/methods ; Male ; Blood Pressure/drug effects ; Female ; Middle Aged ; Hypertension/drug therapy ; Hypertension/physiopathology ; Drug Therapy, Combination ; Aged ; Bisoprolol/administration & dosage ; Bisoprolol/therapeutic use ; Amlodipine/administration & dosage ; Adult ; Indapamide/administration & dosage ; Indapamide/therapeutic use
    Chemical Substances Antihypertensive Agents ; Bisoprolol (Y41JS2NL6U) ; Amlodipine (1J444QC288) ; Indapamide (F089I0511L)
    Language English
    Publishing date 2024-02-28
    Publishing country Netherlands
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 605532-1
    ISSN 1473-5598 ; 0263-6352 ; 0952-1178
    ISSN (online) 1473-5598
    ISSN 0263-6352 ; 0952-1178
    DOI 10.1097/HJH.0000000000003683
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top